rs2040410 — HLA-DQA1 HLA-DQ Autoimmune Tag SNP

Intronic tag SNP near HLA-DQA1 that marks the DR3 (DRB1*0301-DQA1*0501-DQB1*0201) haplotype; the T allele tracks the highest-risk HLA genotype for type 1 diabetes and is associated with systemic lupus erythematosus, sarcoidosis, and HLA-mediated immune dysregulation relevant to atopic disease

See your personal result for HLA-DQA1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The HLA-DQ Immune Recognition Gateway

Deep inside chromosome 6 lies the major histocompatibility complex (MHC) — the most gene-dense region of the human genome and the strongest known genetic determinant of autoimmune disease. rs2040410 sits within this region, just downstream of the HLA-DQA111 HLA-DQA1
Human Leukocyte Antigen DQ alpha-1 chain gene. It acts as a tag marker: its T allele (reported as "A" in some older publications using the minus-strand convention) travels in near-perfect linkage with DRB1*0301, the allele that defines the DR3 branch of the highest-risk type 1 diabetes haplotype.

The Mechanism

HLA-DQ molecules are heterodimeric proteins assembled from an alpha chain (encoded by DQA1) and a beta chain (encoded by DQB1). Together they form a peptide-binding groove that presents antigens to CD4+ T cells. The specific shape of this groove — determined by which DQA1 and DQB1 alleles you carry — determines which peptides trigger immune responses and which are ignored.

The DR3 haplotype (DRB1*0301-DQA1*0501-DQB1*0201, also called DR3-DQ2) forms a groove with unusual binding properties: it presents a wide range of self-peptides and foreign antigens, but it also skews thymic selection of T cells in ways that increase susceptibility to autoimmune activation. HLA-DQ222 HLA-DQ2
The DQ2 heterodimer is present in approximately 95% of celiac disease patients, and DQ2 homozygotes face a substantially higher risk than heterozygotes. The DR3-DQ2 haplotype is independently associated with type 1 diabetes, SLE, Sjögren's syndrome, and other conditions in which loss of tolerance to self-antigens is the central event.

rs2040410 itself is a non-coding downstream variant; it does not change any protein. Its value is as a proxy: the T allele captures the DR3 haplotype status from a standard SNP array, enabling high-throughput identification without the labour-intensive HLA typing33 HLA typing
Traditional high-resolution HLA typing involves sequencing the DRB1, DQA1, and DQB1 loci directly — a process that costs ~$30 per sample versus ~$6 for SNP-based screening required for classical allele calling.

The Evidence

Barker et al. 200844 Barker et al. 2008
Barker JM et al. Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype: potential for rapid screening. Diabetes 2008;57(11):3152-5. established rs2040410 as a tag for DRB1*0301 (R²=0.872) and showed that combining this SNP with rs7454108 (which tags DQB1*0302) identifies the DR3/4-DQ8 compound heterozygous genotype with 98.5% sensitivity and 99.7% specificity across 5,019 participants from the Type 1 Diabetes Genetics Consortium. In an independent DAISY cohort this rose to 100% sensitivity and specificity. The DR3/4-DQ8 genotype — marked by carrying both the T allele at rs2040410 and the C allele at rs7454108 — accounts for roughly 30–50% of childhood-onset type 1 diabetes cases in European populations.

Aly et al. 200655 Aly et al. 2006
Aly TA et al. Extreme genetic risk for type 1A diabetes. PNAS 2006;103(38):14074-9. followed siblings of type 1 diabetes probands who carried the DR3/4-DQ8 genotype and shared both HLA haplotypes with their affected sibling. Cumulative risk of islet autoimmunity reached 85% by age 15 — describing what the authors called "extreme genetic risk," three to four times higher than previously reported for any HLA configuration.

Beyond type 1 diabetes, the DR3 haplotype (and therefore the T allele at rs2040410) is consistently associated with systemic lupus erythematosus, Sjögren's syndrome, and sarcoidosis — conditions all involving dysregulated immune recognition of self-antigens through the DR3-DQ2 peptide-presentation axis.

Practical Actions

Carrying the T allele at rs2040410 does not mean you have or will develop type 1 diabetes or another autoimmune condition — DR3/4-DQ8 homozygotes in the general population have approximately 5% autoantibody prevalence by age 7. The risk is probabilistic and context-dependent. For carriers, the clinically actionable steps focus on monitoring for the earliest signs of autoimmune activation, since several conditions in the DR3-DQ2 risk constellation respond well to early intervention. Coeliac screening is particularly relevant because DQ2 (encoded by the DQA1*0501-DQB1*0201 alleles that travel with this haplotype) is a necessary precondition for gluten-triggered autoimmunity.

Interactions

rs2040410 (DR3 tag) and rs7454108 (DQ8 tag, DQB1*0302 proxy) are used together to identify the compound DR3/4-DQ8 genotype — the highest-risk type 1 diabetes HLA configuration. Individuals heterozygous for both markers (AG at rs7454108 and CT at rs2040410) merit the highest clinical vigilance. The interaction is not additive in a simple sense: the DR3/4-DQ8 combination confers significantly more risk than either the DR3 or DR4 haplotype alone, because the trans DQ heterodimer (DQA1*0301/DQB1*0201) is itself a high-affinity presenter of self-peptides.

Genotype Interpretations

What each possible genotype means for this variant.

CC Common Haplotype Normal

Standard immune recognition profile; DR3 haplotype absent

The CC genotype confirms that neither copy of your chromosome 6 carries the DRB1*0301 allele tracked by rs2040410. The T allele frequency is approximately 7% in Europeans and less than 3% in African and South Asian populations, making CC the overwhelmingly common configuration worldwide.

This does not eliminate all HLA-based autoimmune risk — other high-risk haplotypes exist (e.g., DR4-DQ8, DRB1*0401), and non-HLA genetic factors also contribute. However, for the specific conditions most strongly tied to the DR3-DQ2 haplotype (type 1 diabetes as DR3/4-DQ8, coeliac disease, SLE via the 8.1 ancestral haplotype), the CC result is reassuring.

CT DR3 Heterozygote Intermediate

One copy of the DR3 haplotype; elevated autoimmune susceptibility

Heterozygous DR3 carriers (CT at rs2040410) present the HLA-DQ2.5 heterodimer (DQA1*0501-DQB1*0201) on at least one allele. This DQ2.5 molecule binds a broader range of peptide antigens than most other HLA-DQ variants and is the required molecular partner for coeliac-associated gluten T-cell responses.

If the opposite chromosome carries DR4 (identifiable via rs7454108), the compound DR3/4-DQ8 genotype elevates type 1 diabetes risk markedly: siblings of T1D probands sharing the DR3/4-DQ8 haplotype face up to 85% cumulative autoimmunity risk by age 15 (Aly et al. 2006). In the general population with DR3/4-DQ8, autoantibody prevalence is approximately 5% by age 7 — elevated but not certain.

The DR3 haplotype is also the central HLA risk factor for SLE (particularly via the extended 8.1 ancestral haplotype: HLA-B8-DRB1*0301-DQA1*0501-DQB1*0201) and contributes to Sjögren's syndrome susceptibility.

TT DR3 Homozygote High Risk

Two copies of the DR3 haplotype; highest DQ2-associated autoimmune risk

DQ2 homozygosity (carrying DQA1*0501-DQB1*0201 on both chromosome copies) is associated with a more severe autoimmune phenotype. In coeliac disease studies, DQ2/DQ2 homozygotes have roughly twice the risk of developing the condition compared with DQ2 heterozygotes, and show higher rates of refractory coeliac disease. The mechanism involves gene-dosage: higher surface density of DQ2 molecules means a greater number of antigen-presenting complexes available to activate gluten-reactive T cells.

For type 1 diabetes, homozygous DR3 (without a DR4 chromosome) confers moderate risk — the DR3/4-DQ8 heterozygous combination is actually considered higher risk than DR3/DR3 because the trans DQ heterodimer formed in the compound genotype is a particularly efficient antigen presenter. However, DR3/DR3 still represents elevated overall autoimmune susceptibility.

Monitoring across multiple DQ2-associated conditions — coeliac disease, dermatitis herpetiformis, type 1 diabetes, and SLE — is clinically prudent for this rare genotype.